Trial Profile

A Multicenter, Randomized, Open-Label, Blinded Endpoint Evaluation, Active-Controlled, Dose-Ranging Study to Compare the Efficacy and Safety of i.v. MAA868 and s.c. Enoxaparin in Adult Patients Undergoing Elective Unilateral Total Knee Arthroplasty

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abelacimab (Primary) ; Enoxaparin sodium
Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
Focus Proof of concept; Therapeutic Use
Sponsors Anthos Therapeutics

18 Sep 2023 Results presented in the Anthos Therapeutics Media Release.
14 Sep 2021 Results published in the European Heart Journal
19 Jul 2021 Results comparing the efficacy and safety of abelacimab administered postoperatively with the efficacy and safety of enoxaparin in patients undergoing total knee arthroplasty published in the New England Journal of Medicine

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com